{
  "id": 10701428,
  "title": "UniQure's AMT-130 Shows Continued Slowing Of Huntington's Disease Progression",
  "url": "https://urgent.news/2026/09/29/uniqures-amt-130-shows-continued-slowing-of-huntingtons-disease",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-29T13:04:12.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/uniqures-amt-130-shows-continued-slowing-huntingtons-disease-progression"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Tuesday, uniQure (QURE) reported new data showing its investigational gene therapy AMT-130 continued to slow measures of Huntington's disease progression in patients followed for up to 48 months.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}